Valeant Pharmaceuticals/Medicis Pharma

Target: Medicis Pharma
Buyer: Valeant Pharmaceuticals
Price: $2.6 billion
Closed: Dec. 11, 2012

Valeant Pharmaceuticals' ($VRX) buyout of Medicis was just one in a string of dozens the Canadian company has pulled off, although one of its largest. Valeant CEO J. Michael Pearson calls dermatology Valeant's most important business, and with the Medicis deal it leapfrogs the drugmaker to No. 1 from No. 3 in the category. The group should generate about $2.5 billion in annual sales for the company.

The $2.6 billion paid represented a 39% premium. Pearson brushed off some analyst concerns that the price was unreasonable given that acne drug Solodyn generated 40% of Medicis' annual sales, makes up about 75% of its earnings and may be fading.

With Medicis, Valeant also got the Botox competitor Dysport, and Restylane, a wrinkle-filler that competes with Allergan's ($AGN) Juvéderm. The company likes the fact that because dermatology buys tend to be out-of-pocket for patients, they're not as vulnerable to government budget-cutting (though they can be vulnerable to a sluggish economy).

Valeant Pharmaceuticals/Medicis Pharma

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.